Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

May 31, 2027

Conditions
Functional DyspepsiaProbioticsDepressionAnxiety
Interventions
DRUG

Clostridium butyricum

"Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Clostridium butyricum 1260 mg twice daily.~Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Clostridium butyricum 1260 mg twice daily."

DRUG

placebo

"Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency).~Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency)."

All Listed Sponsors
lead

Xijing Hospital of Digestive Diseases

OTHER

NCT07182890 - Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia | Biotech Hunter | Biotech Hunter